About Novomics
Novomics is a Healthcare company based in Seoul (South Korea) founded in 2010. Molecular diagnosis systems for cancer treatment are developed. Novomics has raised $3.41 million across 2 funding rounds from investors including Yuanda Financial Holdings, Partners Group and ClinicalTrials.gov. Its chief executive, as recorded, is Huh Yongmin. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is Novomics Co., Ltd.
Company details
Novomics was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Molecular diagnostic systems for cancer are developed, focusing on assays that predict post-surgery prognosis in advanced gastric cancer. The flagship nProfiler-1 assay measures nine gene expressions via RT-qPCR, with analysis performed by the nDx-1 algorithm software. Companion diagnostics for lung and colorectal cancers are also under development using the same platform.
- Headquarters Seoul, South Korea
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website novomics.com
- Social LinkedIn
- Legal Name Novomics Co., Ltd
- Annual Revenue$4.63 K (USD)as on Dec 31, 2019
- Total Equity Funding$3.41M (USD)
in 2 rounds
- Latest Funding Round$3.41M (USD), Series A
Dec 2016
- InvestorsYuanda Financial Holdings
& 4 more
Funding Insights of Novomics
Novomics has successfully raised a total of $3.41M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.41 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.41M
- Total Rounds 2
- Last Round Series A — $3.41M
- Investors Count 5
All 2 funding rounds of Novomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $3.41M | Series A | – | – | |
| Jun 2015 | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Novomics
Novomics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Yuanda Financial Holdings, Partners Group and ClinicalTrials.gov.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A private investment holding company focused on middle market technology. | svip.com | Palm Beach, United States | ||
Private equity funds are managed across multiple sectors globally. | 1996 | partnersgroup.com | Baar, Switzerland | |
South-Korea based VC firm | 2012 | megainv.co.kr | Seoul, South Korea | |
Financial services provider | 1961 | yuanta.com | Taipei, Taiwan | |
Clinical studies worldwide are registered in a public database. | 2000 | clinicaltrials.gov | Bethesda, United States |
Investor details for Novomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novomics
1 people are tracked at Novomics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Huh Yongmin | CEO | Leadership |
Complete people profiles for Novomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Novomics
3 dated milestones of Novomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Novomics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $3.4M.
Web traffic of Novomics
The website of Novomics (novomics.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 208.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novomics
Complete news archive for Novomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novomics
Novomics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Novomics is headquartered in Seoul, South Korea.
Huh Yongmin is the CEO of Novomics, as recorded in our data.
Novomics is a funded company, having raised a total of $3.41M across 2 funding rounds to date.
Annual revenue of Novomics is $4.63K as on Dec 31, 2019.
Novomics was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Molecular diagnostic systems for cancer are developed, focusing on assays that predict post-surgery prognosis in advanced gastric cancer. The flagship nProfiler-1 assay measures nine gene expressions via RT-qPCR, with analysis performed by the nDx-1 algorithm software. Companion diagnostics for lung and colorectal cancers are also under development using the same platform.
Novomics has 5 investors. Key investors include Yuanda Financial Holdings, Partners Group, ClinicalTrials.gov, Mega Investment, and SV Investment Partners.
Novomics operates through Novomics Co., Ltd.